![\"\"](\"https:\/\/www.opge.org\/wp-content\/uploads\/2024\/05\/Imagen-1.png\")
<\/p>\nEl Worldwide Registry on the Management of Helicobacter Pylori Infection (WorldHpReg) es la uni\u00f3n de m\u00faltiples registros multic\u00e9ntricos prospectivos internacionales sobre el manejo de la infecci\u00f3n por Helicobacter pylori y su tratamiento en la pr\u00e1ctica cl\u00ednica de los gastroenter\u00f3logos.<\/p>\n
WorldHpReg nace en 2021 bajo el impulso del European Registry on Helicobacter pylori Management (Hp-EuReg) y, actualmente, cuenta con la participaci\u00f3n de las regiones de Latinoamerica, \u00c1frica, Australia, Canad\u00e1, la Asociaci\u00f3n de Naciones de Asia Sudoriental, Estados Unidos, Pakist\u00e1n, Arabia Saud\u00ed, India, Jordania y Nueva Zelanda.
\n\u00bfCu\u00e1l es el objetivo del WorldHpReg?<\/p>\n
La gran diversidad de reg\u00edmenes y l\u00edneas de tratamiento para la erradicaci\u00f3n de Helicobacter pylori y la diferente eficacia de los mismos, debida sobre todo al aumento de las resistencias antibi\u00f3ticas bacterianas y a las diferencias regionales, requiere un continuo an\u00e1lisis cr\u00edtico de la pr\u00e1ctica cl\u00ednica, evaluando sistem\u00e1ticamente la eficacia y seguridad de los diversos reg\u00edmenes y el coste-efectividad de las diferentes estrategias diagn\u00f3stico-terap\u00e9uticas.<\/p>\n
Un Registro Mundial sobre el manejo de H. pylori puede ayudar a dise\u00f1ar tratamientos eficaces y optimizados que reduzcan el n\u00famero de retratamientos, pruebas diagn\u00f3sticas y la aparici\u00f3n de patolog\u00edas asociadas como \u00falceras p\u00e9pticas y c\u00e1nceres g\u00e1stricos. Por lo tanto, la evaluaci\u00f3n de la pr\u00e1ctica cl\u00ednica real mediante registros no intervencionistas puede ayudar a mejorar el dise\u00f1o y la organizaci\u00f3n de un Consenso sobre el manejo de la infecci\u00f3n por H. pylori en cada territorio.<\/p>\n
Generalmente existe un retraso desde la publicaci\u00f3n de las recomendaciones hasta su implantaci\u00f3n en la pr\u00e1ctica cl\u00ednica habitual, alcanzando a veces su plena penetraci\u00f3n despu\u00e9s de haber quedado obsoletas. Es fundamental realizar estudios prospectivos, en vida real que nos permitan crear herramientas capaces de proporcionar datos para evaluar la pr\u00e1ctica y las tendencias de los resultados obtenidos inicialmente a nivel local, regional y mundial.<\/p>\n
El objetivo principal del WorldHpReg es obtener una base de datos que registre sistem\u00e1ticamente una muestra amplia y representativa de la pr\u00e1ctica cl\u00ednica habitual de los gastroenter\u00f3logos en cada territorio para producir estudios descriptivos del manejo de la infecci\u00f3n por H pylori. Con los datos epidemiol\u00f3gicos obtenidos, se pueden dise\u00f1ar mejores estrategias terap\u00e9uticas de acuerdo con la evidencia, los f\u00e1rmacos disponibles y la accesibilidad a las tecnolog\u00edas sanitarias de cada realidad.<\/p>\n
<\/p>\n
HP-LATAMReg (@hplatamreg)
\nEl Hp-LATAMReg es el registro de la pr\u00e1ctica de los gastroenter\u00f3logos latinoamericanos en el manejo de la infecci\u00f3n por Helicobacter pylori y su tratamiento.
\nEl Hp-LATAMReg es una iniciativa de la Sociedad Chilena de Gastroenterolog\u00eda y la Organizaci\u00f3n Panamericana de Gastroenterolog\u00eda (OPGE).
\nEl registro latinoamericano crece d\u00eda a d\u00eda, al 24 de abril 2023 ten\u00eda 2.497 pacientes.<\/p>\n
<\/p>\n
![\"\"](\"https:\/\/www.opge.org\/wp-content\/uploads\/2024\/05\/nota_1.png\")
<\/p>\n
<\/p>\n
Relaci\u00f3n de responsables, centros y pa\u00edses registrados en el Hp-LATAMReg hasta el momento de la publicaci\u00f3n.<\/p>\n
<\/p>\n
M\u00c9XICO
\n\u2022 Remes-Troche, Jose Maria. Universidad Veracruzana, Veracruz, M\u00e9xico.
\n\u2022 Gonz\u00e1lez Huezo, Maria Sara\u00ed. Instituto de Seguridad Social del Estado de M\u00e9xico y Municipios, Toluca, M\u00e9xico.
\n\u2022 Bosques Padilla, Francisco Javier. Tecnol\u00f3gico de Monterrey, Monterrey, Nuevo Le\u00f3n, M\u00e9xico.
\n\u2022 Coss Adame, Enrique. Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico.
\n\u2022 Velarde Ruiz Velasco, Jos\u00e9 Antonio. Hospital Civil de Guadalajara, Guadalajara, Jalisco, M\u00e9xico.
\n\u2022 Higuera de La Tijera, F\u00e1tima. Hospital General de M\u00e9xico Dr. Eduardo Liceaga, Ciudad de M\u00e9xico, Ciudad de M\u00e9xico, M\u00e9xico.
\n\u2022 Ra\u00f1a-Garibay, Ricardo. Hospital Espa\u00f1ol de M\u00e9xico, Ciudad de M\u00e9xico, M\u00e9xico.
\n\u2022 Flores Rendon, Ricardo. Baja California Instituto de Seguridad y Servicios Sociales de los Trabajadores del Gobierno y Municipios del Estado de Baja California, Tijuana, M\u00e9xico.
\n\u2022 G\u00f3mez-Escudero, Octavio. Hospital Angeles Puebla, Puebla, M\u00e9xico.
\n\u2022 Yamamoto Furusho, Jes\u00fas. Hospital M\u00e9dica Sur, Ciudad de M\u00e9xico, M\u00e9xico.
\n\u2022 Valdes, Eumir Israel Ju\u00e1rez. Hospital Ju\u00e1rez de M\u00e9xico, M\u00e9xico City, M\u00e9xico.
\n\u2022 Ortiz-Olvera, Nayeli X. UMAE CMN Sigle XXI IMSS, Ciudad de M\u00e9xico, M\u00e9xico.<\/p>\n
PER\u00da
\n\u2022 Piscoya-Rivera, Alejandro. Hospital Guillermo Kaelin de la Fuente, Lima, Per\u00fa.
\n\u2022 Ram\u00edrez Garc\u00eda, Juan. Cl\u00ednica Liga contra el C\u00e1ncer, Lima, Per\u00fa.
\n\u2022 Cedr\u00f3n-Cheng, Hugo Guillermo. Cl\u00ednica Anglo Americana, Lima, Per\u00fa.
\n\u2022 Cabrera Hinojosa, Dacio H\u00e9ctor. Hospital Nacional Dos de Mayo, Lima, Per\u00fa.
\n\u2022 Otoya, Guillermo. Hospital Guillermo Almenara Irigoyen, Lima, Per\u00fa.<\/p>\n
CHILE
\n\u2022 Riquelme, Arnoldo. Reyes-Placencia, Diego. Vargas, C\u00e9sar. Medel-Jara, Patricio. Latorre, Gonzalo. Chahu\u00e1n, Javier. Pizarro, Margarita. Binder, Mar\u00eda Victoria. Bustamante, Miguel. Dukes, Eitan. Mart\u00ednez, Francisca. Silva, Felipe. Candia, Roberto. Vargas Dom\u00ednguez, Jos\u00e9 Ignacio. Gastroenterolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile.
\n\u2022 Von Muhlenbrock, Christian. Cl\u00ednica Universidad de los Andes, Las Condes, Regi\u00f3n Metropolitana Sant, Chile.
\n\u2022 Arenas, Alex. Cl\u00ednica Alemana de Santiago SA, Vitacura, Metropolitan Region, Chile.
\n\u2022 Mansilla Vivar, Rodrigo. Hospital Puerto Montt, Puerto Montt, Llanquihue, Chile.<\/p>\n
ARGENTINA
\n\u2022 Laudanno, Oscar. Instituto Doctor Alfredo Lanari, Buenos Aires, Argentina.
\n\u2022 Ahumaran, Gabriel. Cl\u00ednica Monte Grande, Buenos Aires, Argentina.
\n\u2022 Rodr\u00edguez, Pablo C\u00e9sar. Instituto Modelo C\u00f3rdoba, C\u00f3rdoba, Argentina.
\n\u2022 Bedini, Oscar Alfredo. Centro de Endoscop\u00eda Digestiva, Rosario, Argentina.
\n\u2022 Ustares, Fernando. Sanatorio Lavalle, Jujuy, Argentina.<\/p>\n
COLOMBIA
\n\u2022 Otero, William. Marulanda, Hernando. Universidad Nacional de Colombia, Bogot\u00e1, Colombia.
\n\u2022 Otero, Lina. Otero, Elder. Centro de Gastroenterolog\u00eda y Endoscop\u00eda, Bogot\u00e1, Colombia.
\n\u2022 Trespalacios, Alba. Pontificia Universidad Javeriana, Bogot\u00e1, Colombia.<\/p>\n
COSTA RICA
\n\u2022 Campos Nu\u00f1ez, Christian. Hospital Cl\u00ednica Biblica, San Jos\u00e9, Costa Rica.<\/p>\n
ECUADOR
\n\u2022 Hanna-Jairala, Ignacio. Hospital Miguel H Alc\u00edvar, Guayaquil, Guayas, Ecuador.<\/p>\n
ESPA\u00d1A
\n\u2022 Gisbert, Javier P., Nyssen, Olga P., Parra, Pablo. Hospital Universitario de La Princesa, Madrid, Spain.
\n\u2022 Cano-Catal\u00e0, Anna. GOES research group, Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa, Manresa. Institut de Recerca i Innovaci\u00f3 en Ci\u00e8ncies de la Vida i de la Salut de la Catalunya Central (IRIS-CC), Vic, Spain.
\n\u2022 Moreira, Leticia. Hospital Cl\u00ednic de Barcelona, Barcelona, Catalunya, Spain.<\/p>\n
<\/p>\n
<\/p>\n
El Hp-LATAMReg es un registro abierto para todos los que deseen participar en los diferentes pa\u00edses de Latinoamerica.<\/strong><\/p>\n Si desea saber los requisitos, debe comunicarse con el Dr. Diego Reyes-Plasencia (dmreyes@uc.cl).<\/strong><\/p>\n <\/p>\n <\/p>\n PUBLICACIONES DEL PRODUCTO DEL Hp-LATAMReg HASTA MAYO DEL 2024.<\/strong><\/p>\n <\/p>\n 1. First description of the data from the Latin American Registry on the management of Helicobacter pylori infection (Hp-LATAMReg).<\/strong> Objective: There is limited information regarding the best approach for Helicobacter pylori management in Latin America. Our aim was to describe the main characteristics of the H. pylori eradication treatment in Latin America.<\/p>\n Materials and Methods: A multicenter, prospective, international registry (Hp-LATAMReg) was conducted. Information about therapies used by gastroenterologists in five countries (Chile, Argentina, Mexico, Peru, and Colombia) from 2015 to 2023 was registered in an e-CRF AEG-REDCap database. The modified intention-to-treat (mITT) effectiveness, safety, and adherence was analyzed for the first-line regimens. Data were quality reviewed.<\/p>\n Results: We registered 681 patients, of which 599 (88%) were treatment-na\u00efve. The most frequent indication for treatment was dyspepsia (n=443, 65%). The most commonly prescribed first-line therapies were: proton pump inhibitor (PPI)-amoxicillin (A)-clarithromycin (C), PPI-C-A-Metronidazole (M), PPI-A, PPI-C-A-Bismuth (B) and PPI-A-Levofloxacin (L). Most of the regimes were 14-day long (n=546,93%), and administered low-dose PPIs (n=282, 47%). The first-line mITT overall effectiveness ranged from 80% to 91%, and PPI+C+A+M was the only regimen that achieved over 90% eradication (Table). The incidence of at least one adverse event was 35%, the most common being abdominal pain (17%). Conclusions: In Latin America, optimal (>90%) effectiveness was only obtained with 14-day concomitant non-bismuth quadruple therapy (PPI-C-A-M). Triple therapies and low-dose PPIs are still commonly prescribed, leaving room for improvement.<\/p>\n <\/p>\n 2. Helicobacter pylori diagnostic tests and indications of treatment from the Latin American registry on the management of Helicobacter pylori infection (Hp-LATAMReg)<\/strong> Background: There is limited information regarding the best approach for Helicobacter pylori (H.pylori) management in Latin America.<\/p>\n Objectives: Describe the H. pylori diagnostic tests and indications of treatment in Latin America.<\/p>\n Methods: A multicenter, retrospective, international registry (Hp-LATAMReg) was conducted. Information about therapies used by gastroenterologists in six countries (Argentina, Chile, Colombia, Costa Rica, Mexico, and Peru) from 2015 to 2023 was registered in an e-CRF AEG-REDCap database. The most frequent indications for treatment and diagnostic tests before and after eradication treatment were described.<\/p>\n Results: 1,378 patients were registered, of which 933 (68%) were female. The mean (SD) age of the patients was 53 (14) years. 524 patients (38%) were from Mexico, 210 patients (15%) from Argentina, 210 (15%) from Chile, 200 (14%) from Colombia, 176 (13%) from Peru and 58 (4.2%) from Costa Rica. 1218 (89%) were treatment na\u00efve. The most frequent indication for treatment were non-investigated dyspepsia (n=526, 38%) and dyspepsia with normal endoscopy (n=334, 24%). The main H. pylori diagnostic methods before the eradication treatment were: histology (n=905, 67%), rapid urease test (RUT) (n=196, 14%) and 13C urea breath test (UBT) (n=180, 13%). To assess post-treatment eradication, the most frequent H. pylori diagnostics test used were: stool antigen (SA) monoclonal test (n=530, 39%), 13C UBT (n=400, 29%) and 14C UBT (n=215, 16%). There were statistical differences between the countries regarding the indication for treatment and the diagnostics methods before and after the eradication therapy (Table 1).<\/p>\n Conclusions: In Latin America, there was marked heterogeneity between the countries regarding the main indications of treatment and the most frequently used diagnostics tests for H. pylori infection. It is necessary a consensus on the management of H. pylori infection in Latin America.<\/p>\n <\/p>\n 3. Abstract presentado para la UEGW 2024.<\/strong><\/p>\n Background: Helicobacter pylori infection is a public health problem in Latin America. The aim was to describe the main Helicobacter pylori eradication therapies, their eradication rates, adherence, side effects, proton pump inhibitor (PPI) potency and length of treatment.<\/p>\n Methods: A multicenter, prospective, international registry (Hp-LATAMReg) was conducted. Information about therapies used by gastroenterologists in seven countries (Argentina, Chile, Colombia, Costa Rica, Ecuador, Mexico, and Peru) from 2015 to 2024 was registered in an e-CRF AEG-REDCap database. The modified intention-to-treat (mITT) effectiveness, safety, and adherence was analyzed for the first-line regimens. The length of the treatment and the proton pump inhibitor (PPI) dose were analyzed too. Conclusions: In Latin America, quadruples therapies were the only therapies which had an effectiveness above 90%. DT had the lowest side effects rate with an acceptable eradication rate. SCTT had an unacceptable eradication rate and a high side effects rate but still was the therapy most frequently used in Latin America.<\/p>\n <\/p>\n Table 1. Eradication rate, side effects rate, acceptable adherence rates, high PPI potency and length of the treatment of the different schemes. *Chi square test. mITT = modified intention to treat; SCTT = Standard clarithromycin-based triple therapy; DT = Dual therapy; PPI = Proton pump inhibitor; C = Clarithromycin; A = Amoxicillin; B = Bismuth salts; M = Metronidazole; L = Levofloxacin; T = Tetracycline; D = Doxycycline.<\/p>\n <\/p>\n 4. Posters presentados en el DDW Washington 2024<\/strong><\/p>\n <\/p>\n El Worldwide Registry on the Management of Helicobacter Pylori Infection (WorldHpReg) es la uni\u00f3n de m\u00faltiples registros multic\u00e9ntricos prospectivos internacionales sobre el manejo de la infecci\u00f3n por Helicobacter pylori y su tratamiento en la pr\u00e1ctica cl\u00ednica de los gastroenter\u00f3logos. WorldHpReg nace en 2021 bajo el impulso del European Registry on Helicobacter pylori Management (Hp-EuReg) y, […]<\/p>\n","protected":false},"author":1,"featured_media":3353,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[100],"tags":[],"class_list":["post-3184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/posts\/3184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.opge.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3184"}],"version-history":[{"count":5,"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/posts\/3184\/revisions"}],"predecessor-version":[{"id":3352,"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/posts\/3184\/revisions\/3352"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.opge.org\/index.php?rest_route=\/wp\/v2\/media\/3353"}],"wp:attachment":[{"href":"https:\/\/www.opge.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.opge.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.opge.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nPresentado en el European Helicobacter and Microbiota Study Group durante el 36th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Antwerp, Beligium. Set. 2023.<\/p>\n
\nAcceptable adherence, defined as >90% of drug intake, was observed in 97%.<\/p>\n
\nPresentado para la Semana Panamericana de Gastroenterolog\u00eda. Chile 2023.
\nPublicado en la Revista de Gastroenterolog\u00eda del Per\u00fa. Abstract S95.
\nDOI: https:\/\/doi.org\/10.47892\/rgp.2023.43Supl1.1616<\/p>\n
\n+Results: 2,511 patients were registered, of which 2,323 (93%) were treatment-na\u00efve. The most commonly prescribed first-line therapies (n=2,163, 86%) were analyzed: standard clarithromycin-based triple therapy (SCTT) (PPI-amoxicillin (A)-clarithromycin (C); n=771, 29%), PPI-C-A-Metronidazole (M) (n=362, 14%), dual therapy (DT) (PPI-A; n=274, 11%), PPI-M-Doxycycline (D)-B (n=198,7.9%), PPI-M-Tetracycline (Tc)-Bismuth (B) (n=184, 7.3%), PPI-A-M-B (n=156,6.2%), PPI-C-A-B (n=113, 4.5%), and PPI-A-Levofloxacin (L) (n=105, 4.2%).
\nThe first-line mITT overall effectiveness ranged from 73% to 95%, being the PPI-A-M-B and PPI-C-A-M the only therapies which had an eradication rate of more than 90%. The DT had the lowest rate of side effects with a 7.3% (n=20).
\nThe highest rate of side effects was from the PPI-M-D-B (48%, n=95). Good adherence, defined as >90% of drug intake, was observed in 85% (n=2,124), most of the regimes were 14-day long (n=2,028, 81%) and administered high-dose PPIs (54 to 128 mg omeprazole equivalents b.i.d.) (n=1,355, 54%) with differences between the schemes in those characteristics (p<0.01) (Table 1).<\/p>\n![\"\"](\"https:\/\/www.opge.org\/wp-content\/uploads\/2024\/05\/Captura-de-Pantalla-2024-05-28-a-las-12.23.00-1030x599.png\")
<\/p>\n![\"\"](\"https:\/\/www.opge.org\/wp-content\/uploads\/2024\/05\/DDW1.jpg\")
<\/p>\n![\"\"](\"https:\/\/www.opge.org\/wp-content\/uploads\/2024\/05\/ddw2.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"